U.S. markets open in 8 hours 23 minutes

Quoin Pharmaceuticals, Ltd. (QNRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.2601+0.0901 (+2.16%)
At close: 03:50PM EDT
4.1300 -0.13 (-3.05%)
After hours: 07:03PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.1700
Bid0.0000 x 1400
Ask0.0000 x 1100
Day's Range4.1100 - 4.4151
52 Week Range4.1000 - 39.3600
Avg. Volume159,784
Market Cap4.206M
Beta (5Y Monthly)N/A
PE Ratio (TTM)0.01
EPS (TTM)729.5300
Earnings DateNov 08, 2023 - Nov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est132.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for QNRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Quoin Pharmaceuticals, Ltd.
    Daily – Vickers Top Insider Picks for 03/13/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more
  • Zacks Small Cap Research

    QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials

    By M. Marin (NASDAQ:QNRX) READ THE FULL QNRX RESEARCH REPORT Positive early data from clinical studies; open-label study topline data expected in 2H23 Quoin Pharmaceuticals (NASDAQ:QNRX) is advancing clinical studies to evaluate QRX003 for the treatment of Netherton Syndrome (NS) and also developing distribution infrastructure in preparation for the expected commercialization of QRX003 and other

  • NewMediaWire

    Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders

    NEW YORK, NY - (NewMediaWire) - August 09, 2023 - PCG Digital --Quoin Pharmaceuticals (Nasdaq:QNRX), a clinical stage pharmaceutical company specializing in rare and orphan diseases, has achieved significant milestones in its mission to deliver the f...

  • GlobeNewswire

    Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

    Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study Subject’s skin was assessed to be fully clear by Investigator at QRX003 treatment areas Subject also demonstrated key improvements across all other clinical endpoints, including pruritis A majority of patients in both Netherton Syndrome studies are expected to be enrolled by the end of August Both studies are demonstrating an exemplary safety profile for QRX003 Quoin expect